Teduglutide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Teduglutide
   1. Pharmacist Assessment Report
   2. Teduglutide: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Teduglutide: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Teduglutide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use among the candidates is short bowel syndrome, supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
short bowel syndrome	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
11793Q	Revestive	Powder for injection 5 mg with diluent	Valid

Safety Considerations

• Drug Interactions: 17 interaction records were found. One is rated Major (bexarotene). Fifteen are rated Moderate and involve benzodiazepines (alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepic acid, diazepam, estazolam, flurazepam, halazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, triazolam). The remaining record is a pharmacology entry confirming the GLP-2 receptor as the target.
• Class consideration: Teduglutide’s growth-promoting effects raise a caution regarding neoplasia in the gastrointestinal tract. This should be weighed before any new use.

Warnings and contraindications from the product label were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---